Help us: Donate
Follow us on:
×

Menu

Back

Tag: TORC1

Small plate of food
A key gene mediating the effect of dietary restriction on longevity has been identified, improving our understanding of the link between the two and raising the prospect of more targeted therapeutic interventions. Less is more Dietary restriction is one of the most reliable ways to increase longevity, increasing lifespan in species from fruit flies to...
Bread yeast
Building upon previous studies, a new study has unearthed critical facts about the basic biology behind the TORC1 pathway, identifying how caloric restriction leads to a chain of effects that activate the protein Maf1, repress RNA transcription, and slow genomic instability, which is one of the primary hallmarks of aging. A long chain of causes...
Disappointment
ResTORbio announced on Friday 15th that its current phase 3 drug trial for respiratory tract infections did not achieve its primary goal. The drug showed promise in earlier phases of testing, but sadly failed to reduce the incidence of respiratory tract infections in patients aged 65 and above. A setback for RTB101 This news has...
The Journal Club returns for a Halloween special, and this time around, Dr. Oliver Medvedik is taking an in-depth look at a recent paper showing that a combination of three drugs had a synergistic effect and increased lifespan greatly in fruit flies. The drugs all target parts of the nutrient sensing system which controls metabolism,...
Rapamycin is a promising anti-aging therapeutic derived from a bacterium that was first found on Easter Island (it's named for Rapa Nui, the official name of Easter Island). It inhibits mTOR (mechanistic target of rapamycin), thus inhibiting the immune system response that would, in some cases, lead to organ rejection. This is the on-label, FDA-approved...
Last year, resTORbio announced the positive results of its phase 2b human trial, which targeted the aging immune system with an immune system-boosting drug. Now, the company has announced the news that its therapy is moving to a phase 3 study later this year after successful negotiation with the FDA. Targeting the mTOR pathway of...